©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Pathophysiol. May 15, 2014; 5(2): 63-70
Published online May 15, 2014. doi: 10.4291/wjgp.v5.i2.63
Published online May 15, 2014. doi: 10.4291/wjgp.v5.i2.63
Implication of miRNAs for inflammatory bowel disease treatment: Systematic review
Wei-Xu Chen, Li-Hua Ren, Rui-Hua Shi, Department of Gastroenterology, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China
Author contributions: Chen WX wrote and reviewed the manuscript; Ren LH contributed to the work; Shi RH reviewed and assisted with editing the manuscript.
Correspondence to: Rui-Hua Shi, MD, PhD, Department of Gastroenterology, the First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, Jiangsu Province, China. ruihuashi@126.com
Telephone: +86-25-83674636 Fax: +86-25-83674636
Received: December 26, 2013
Revised: February 8, 2014
Accepted: April 16, 2014
Published online: May 15, 2014
Processing time: 145 Days and 0.6 Hours
Revised: February 8, 2014
Accepted: April 16, 2014
Published online: May 15, 2014
Processing time: 145 Days and 0.6 Hours
Core Tip
Core tip: MicroRNAs (miRNAs) are a class of small, noncoding RNA molecules that post-transcriptionally regulate gene and protein expression. Recent studies have identified altered miRNA profiles in inflammatory bowel disease (IBD). Special miRNAs which suppress functional targets have been found to play a critical role in regulating key pathogenic mechanism in IBD. In this review, we discuss the possibility to use miRNAs as biomarkers and therapeutic target in IBD.